What is orforglipron is a common question because it acts on the same receptor as semaglutide without being a peptide. Researchers at Chugai Pharmaceutical and Eli Lilly first described it in 2020. The five Phase 3 trials summarized here enrolled more than 9,700 adults with obesity or type 2 diabetes.
Quick answer: Orforglipron is a prescription medicine sold in the United States as Foundayo. It activates the GLP-1 receptor, like semaglutide and liraglutide, but it is a small molecule rather than a peptide. Its US label lists one indication: reducing excess body weight and maintaining weight reduction in adults. Eli Lilly holds the approval.
Is orforglipron a peptide?
No. A peptide is a chain of amino acids joined by peptide bonds; Vitrapep's guide to what peptides are explains the category. Orforglipron has no amino acid chain. PubChem lists its formula as C48H48F2N10O5 and its molecular weight as 883.0 g/mol (PubChem).
The medicine itself contains orforglipron calcium, a salt form. The Foundayo label gives its formula as C48H47F2N10O5.[0.5]Ca, with a molecular weight of 902.0 g/mol. The label describes a white to light brown solid that does not dissolve in water.
Semaglutide is a different kind of molecule. Its label describes a peptide backbone made by yeast fermentation, with a fatty acid side chain attached (oral semaglutide label).
In 2020, its discoverers wrote that all approved GLP-1 receptor agonists were peptide based (Kawai et al., 2020). Foundayo is the only non-peptide product on FDA's November 2026 list of approved GLP-1 receptor agonists (FDA, 2026). Table 1 compares the two molecules.
Is orforglipron a peptide
| Feature | Orforglipron | Semaglutide | Source |
|---|---|---|---|
| Molecule type | Small molecule, not a peptide | Modified peptide with a fatty acid side chain | PubChem; semaglutide label |
| Molecular formula | C48H48F2N10O5 | C187H291N45O59 | PubChem; semaglutide label |
| Molecular weight | 883.0 g/mol | 4113.58 g/mol | PubChem; semaglutide label |
| Main elimination pathway | Liver enzyme CYP3A4, to oxidative metabolites | Breakdown of the peptide backbone and fatty acid chain | Both labels |
| Elimination half-life | About 29 to 49 hours | About one week | Both labels |
| Activity at rat and mouse GLP-1 receptors | Not pharmacologically active | Active; caused thyroid C-cell tumors in rodents | Both labels |
| US brand names | Foundayo | Ozempic, Rybelsus, Wegovy | FDA, 2026 |
| First US approval | 2026 | 2017 | Drugs@FDA; FDA, 2026 |
Where did orforglipron come from?
Orforglipron was first described in 2020 under the codes LY3502970 and OWL833. The authors worked at Chugai Pharmaceutical's research division in Japan, Eli Lilly and ConfometRx (Kawai et al., 2020). They wrote that small molecules with good drug properties had proven difficult to obtain for this receptor.
Lilly later described it as a synthetic nonpeptide agonist for type 2 diabetes and obesity (Sloop et al., 2024). Eli Lilly sponsored every trial described on this page and holds the US application (Drugs@FDA).
How does orforglipron activate the GLP-1 receptor?
Kawai and colleagues solved a high-resolution structure of the compound bound to the active GLP-1 receptor. It sat in a distinct pocket in the upper part of the receptor. In cell studies it was a partial agonist. It favored G protein signaling over beta-arrestin, a protein that helps switch receptors off (Kawai et al., 2020).
Binding also depended on tryptophan at position 33 of the receptor, an amino acid found in primates. This helps explain why it acts on human receptors but not rodent ones. In animal studies, it lowered glucose in mice carrying the human receptor. In nonhuman primates, it raised insulin and reduced food intake. The effect sizes were comparable to exenatide, an approved peptide.
A 2024 Lilly study measured a binding constant of 1 nM at the human receptor. In mice carrying that receptor, low receptor occupancy produced a full glucose-lowering response. In rats edited to carry a tryptophan at position 33, orforglipron reduced body weight in diet-induced obesity (Sloop et al., 2024).
The Foundayo label adds that in animal studies, the drug reached and activated neurons in brain regions that regulate appetite. In people, the label says it decreases food intake and delays gastric emptying.
Why does it matter that orforglipron is a small molecule?
The first practical difference is absorption. The oral semaglutide label reports an absolute bioavailability of about 0.4% to 1% for Rybelsus. That tablet contains SNAC, an ingredient the label says helps semaglutide absorb. The Foundayo label reports a geometric mean absolute bioavailability of 77%. SNAC is not among its listed ingredients.
The second difference is how the body clears it. The semaglutide label describes clearance by cutting of the peptide backbone. Orforglipron is instead processed mainly by the liver enzyme CYP3A4. The CYP3A4 pathway creates enzyme-based drug interactions listed on the label.
In label studies, clarithromycin, which blocks CYP3A4, raised orforglipron exposure 3.5-fold. Carbamazepine, which speeds CYP3A4 activity, lowered it by 82%.
The third difference concerns rodent testing. The label reports no tumors in rat and mouse studies, but the drug is inactive in those species. It still carries the class boxed warning, because human relevance of receptor-driven rodent thyroid tumors is undetermined.
What did the main human trials show?
All five Phase 3 trials below were randomized human studies funded by Eli Lilly. Four tested several orforglipron dose groups against placebo or an active comparator. The label notes that its two weight trials used an investigational formulation of the drug.
What did the main human trials show
| Trial | Design and comparator | Population and size | Duration | Primary result |
|---|---|---|---|---|
| ACHIEVE-1 | Double-blind; placebo | 559 adults with early type 2 diabetes managed with diet and exercise | 40 weeks | HbA1c fell 1.24 to 1.48 points, versus 0.41 with placebo |
| ATTAIN-1 | Double-blind; placebo | 3,127 adults with obesity, or overweight plus a related condition, without diabetes | 72 weeks | Body weight fell 7.5% to 11.2%, versus 2.1% with placebo |
| ATTAIN-2 | Double-blind; placebo | 1,613 adults with obesity or overweight and type 2 diabetes | 72 weeks | Body weight fell 5.1% to 9.6%, versus 2.5% with placebo |
| ACHIEVE-3 | Open-label; oral semaglutide | 1,698 adults with type 2 diabetes not controlled on metformin | 52 weeks | HbA1c fell 1.71 and 1.91 points, versus 1.23 and 1.47 with semaglutide |
| ACHIEVE-4 | Open-label; insulin glargine | 2,749 adults with type 2 diabetes and cardiovascular or chronic kidney disease | Median 2 years | Major cardiovascular events in 4.2% versus 5.0%; hazard ratio 0.84 |
ACHIEVE-1, the first Phase 3 report, recorded no severe hypoglycemia (Rosenstock et al., 2025).
In ATTAIN-1, 54.6% of the highest dose group lost at least 10% of body weight, versus 12.9% on placebo. Waist size, systolic blood pressure, triglycerides and non-HDL cholesterol also improved (Wharton et al., 2025). In ATTAIN-2, HbA1c and the other prespecified cardiometabolic measures also improved (Horn et al., 2025).
ACHIEVE-3 met its noninferiority goal for HbA1c against oral semaglutide, and both orforglipron groups also showed superiority on that measure. Gastrointestinal events, discontinuations for adverse events and pulse increases were all higher with orforglipron. The trial was open-label, so participants knew which drug they received (Rosenstock et al., 2026).
ACHIEVE-4 was a cardiovascular safety trial. Its 95% confidence interval for the hazard ratio ran from 0.59 to 1.20, below the preset noninferiority margin of 1.8. Clinically significant or severe hypoglycemia occurred in 6.8% with orforglipron and 19.2% with insulin glargine (Klein et al., 2026).
What side effects are reported for orforglipron?
The Foundayo label pools the two 72-week weight trials, which included 3,155 orforglipron-treated adults. Table 3 shows reactions reported in at least 5% of a treated group. Ranges span the three dose groups.
What side effects are reported for orforglipron
| Adverse reaction | Placebo | Orforglipron groups |
|---|---|---|
| Nausea | 10% | 26% to 35% |
| Constipation | 9% | 20% to 27% |
| Diarrhea | 11% | 21% to 25% |
| Vomiting | 4% | 13% to 24% |
| Dyspepsia | 4% | 12% to 16% |
| Abdominal pain | 7% | 13% to 14% |
| Headache | 7% | 8% to 9% |
| Hair loss | 2% | 4% to 5% |
Eight percent of treated adults stopped because of adverse reactions, versus 3% on placebo. Most of those stops were gastrointestinal. Nausea, vomiting and diarrhea were more frequent early in treatment and decreased over time.
The label also reports tachycardia in 3% versus 0.9%, with a mean heart rate rise of 4 to 5 beats per minute. Hypotension occurred in 2% versus 0.5%. Adjudicated acute pancreatitis occurred in six treated patients and one placebo patient.
The boxed warning covers thyroid C-cell tumors, as explained above. Foundayo is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Other label warnings cover pancreatitis, severe gastrointestinal reactions, kidney injury from dehydration, hypoglycemia, hypersensitivity, diabetic retinopathy complications, gallbladder disease and aspiration during anesthesia.
On November 9, 2026, FDA required all GLP-1 receptor agonist labels, including Foundayo's, to add a warning about NAION, a rare eye condition. Vitrapep's article on FDA's GLP-1 eye-risk warning covers that action. Suspected reactions can be reported to FDA MedWatch at 1-800-FDA-1088.
What is orforglipron's regulatory status?
FDA approved Foundayo on April 1, 2026 (FDA, 2026). It was the fifth approval under the Commissioner's National Priority Voucher pilot program and the first new molecular entity approved through it. FDA said the decision came 50 days after filing.
The approved use, with diet and physical activity, is weight reduction and long-term maintenance in adults with obesity, or overweight with a weight-related condition. The August 2026 label on DailyMed lists no type 2 diabetes indication.
Foundayo was not the first GLP-1 pill. Rybelsus, an oral semaglutide tablet, was approved in 2019. Wegovy tablets followed in December 2025. Foundayo is the first approved GLP-1 receptor agonist that is not a peptide.
In Europe, the CHMP adopted a positive opinion on October 15, 2026, for weight management and type 2 diabetes (EMA, 2026). An opinion is not an approval. On November 18, 2026, EMA's medicine page still showed the opinion stage, awaiting a European Commission decision.
Vitrapep does not sell orforglipron; this page is a reference summary of published research and regulatory information. A research-use label on any product does not make it an approved medicine or legal for people. See research peptides and human-use risks.
How does orforglipron relate to other GLP-1 medicines?
Orforglipron targets the receptor for GLP-1, the gut hormone covered in what is GLP-1. Cell studies found it selective against related receptors in the same family. The GLP-1 class overview and semaglutide complete guide cover the peptide medicines.
ACHIEVE-3 is the only trial here that compared orforglipron directly with semaglutide, and only for HbA1c. Separate trials cannot be compared directly, because populations, durations and analyses differ. See peptide pills, supplements and nasal sprays for other oral products, and how to find a peptide clinical trial for ongoing studies.
Frequently asked questions
Is orforglipron a peptide?
No. It is a small molecule with a molecular weight of 883.0 g/mol. Semaglutide, a peptide, weighs 4113.58 g/mol.
Is orforglipron FDA-approved?
Yes. FDA approved it as Foundayo on April 1, 2026, for weight reduction and long-term maintenance in certain adults.
Was orforglipron the first GLP-1 pill?
No. Rybelsus, an oral semaglutide tablet, was approved in 2019. Foundayo is the first approved GLP-1 receptor agonist that is not a peptide.
What side effects does the Foundayo label list?
Among the most common were nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain and headache. The label also has a boxed warning about thyroid C-cell tumors.
Why does the label warn about thyroid tumors seen in rodents?
Orforglipron does not act on rat or mouse GLP-1 receptors, so rodent studies could not test this effect. Other GLP-1 drugs cause these tumors in rodents, and human relevance is undetermined.
Is orforglipron approved for type 2 diabetes?
Not in the United States, based on the label posted on DailyMed in August 2026. In Europe, the CHMP recommended approval for type 2 diabetes and weight management in October 2026.
What to know now
- Orforglipron is a small-molecule GLP-1 receptor agonist, not a peptide, approved by FDA as Foundayo on April 1, 2026.
- It binds a distinct pocket on the human GLP-1 receptor and does not act on rodent receptors.
- Phase 3 trials showed lower body weight and HbA1c than placebo, with mostly gastrointestinal adverse events.
- The US label covers weight reduction only; a European decision on weight and diabetes uses is pending.
What we’re watching
- ATTAIN-Outcomes (NCT07241390), a placebo-controlled cardiovascular outcomes trial planning 7,140 participants, with primary completion estimated for August 2031.
- The European Commission decision that follows the October 2026 CHMP opinion.
- A Phase 3 trial in adolescents with obesity or overweight (NCT06672939), with primary completion estimated for December 2027.
- Foundayo label updates, including the NAION warning FDA required in November 2026.